Home › Articles › Shingles vaccine: unexpected cardiovascular protection confirmed in 2026
Specialties

Shingles vaccine: unexpected cardiovascular protection confirmed in 2026

1 May 20267 min readClinovus AI Team

Shingles is not just a painful skin disease. Data from 2025–2026, confirmed at ACC 2026, show that VZV reactivation triggers an inflammatory cascade with measurable cardiovascular consequences. The vaccine offers protection well beyond shingles prevention alone.

Key figures: cohort study of 1.27 million people

The pivot study is Korean: over 1.27 million people aged 50+, followed for 6 years, published in the European Heart Journal.[1]

Cardiovascular risk reduction by the shingles vaccine Overall cardiovascular risk −23%Major events (stroke, MI, death) −26%Heart failure −26%Cerebrovascular events −24%Coronary artery disease −22% Kyung Hee University, Seoul · European Heart Journal · 1.27 million participants · 6-year follow-up
Cardiovascular risk reduction after shingles vaccination — cohort study of 1.27 million people

Protection is observed for 8 years, with peak efficacy at 2–3 years. The effect is strongest in men, those under 60 and people with unhealthy lifestyles.

The mechanism: why shingles damages the heart

How shingles increases cardiovascular risk — and how the vaccine protects VZV reactivation Latent varicella-zoster virus Systemic inflammation Pro-inflammatory cytokines Hypercoagulability Arterial & venous thrombosis Endothelial damage Vasculitis, vascular dysfunction ↑ Risk stroke, MI, HF Within 12 months of shingles Shingles vaccine → prevents reactivation → blocks the cascade 2026 bonus: −50% dementia risk (Nature, Feb. 2026) · Shingrix® · >65 yrs
Shingles increases cardiovascular risk via inflammation and coagulation — the vaccine blocks this cascade upstream

ACC 2026: new data on Shingrix®

ACC 2026 data confirm the protective effect of Shingrix® in patients with existing cardiovascular disease — significant reduction in heart attacks, strokes, heart failure and death in the year following vaccination.[2]

The protective effect is likely due to prevention of the systemic inflammation and dangerous blood clots resulting from shingles. By preventing viral reactivation, the vaccine cuts the cascade upstream.

The unexpected bonus: −50% dementia risk

A Nature study (February 2026) of 65,800 Shingrix®-vaccinated vs 263,200 controls shows people over 65 who received two doses have a dementia risk twice as low.[3]

Recommendations for practice in Switzerland

See also our article on automatic SOAP notes with AI.

Frequently asked questions

Is the shingles vaccine recommended in Switzerland?

Yes. The FOPH recommends Shingrix® (2 doses) for all persons aged 65 and over, and from age 50 for immunocompromised individuals. Zostavax® is no longer available.

How does shingles increase cardiovascular risk?

VZV reactivation triggers systemic inflammation, hypercoagulability and endothelial damage — explaining the documented increased risk of stroke, MI and heart failure within 12 months of a shingles episode.

Do the cardiovascular benefits apply to Shingrix® too?

The Korean mega-study concerned Zostavax®. ACC 2026 data confirm the protective effect of Shingrix® in cardiac patients. The Nature study (February 2026) on dementia specifically concerned Shingrix®.

Should patients vaccinated with Zostavax® be re-vaccinated?

Yes. Zostavax® is no longer available and its protection wanes. Shingrix® can be given after at least 2 months. Its immunogenicity and efficacy exceed Zostavax®, with protection maintained beyond 10 years.

Sources and references

  1. Yon DK et al. (2025). Zoster vaccination and cardiovascular events — cohort of 1.27 million. European Heart Journal. medscape.com
  2. ACC 2026. Shingrix® and reduction of major cardiovascular events in high-risk patients. vih.org
  3. Nature (February 2026). Shingrix® and 50% dementia risk reduction in over-65s.
  4. FOPH (2026). Vaccination recommendations — herpes zoster. bag.admin.ch
  5. Ma-Clinique.fr (March 2026). Shingles vaccine and cardiovascular risk reduction. ma-clinique.fr
Disclaimer: this article does not replace official vaccination recommendations (FOPH). Vaccination decisions must be individualised.

Document your vaccination consultations with Clinovus AI

Vaccination history, SOAP note — automatically generated. Hosted in Switzerland, nFADP-compliant.

Try free →
A question about this article?Our team replies within 24h.
support@clinovusai.com